Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study

What Was Tested

The paper reports a study of Abaloparatide, published as a randomized controlled trial.

Its effect in Japanese patients remains unexamined.

Who Took Part

PubMed tags the participants as both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Abaloparatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Abaloparatide.

Some participants received a placebo instead of Abaloparatide, giving a reference point.

This was a randomized, double-blind, placebo-controlled study conducted in Japan.

The primary end point was percentage change in lumbar spine (LS) BMD from baseline at the last visit.

Secondary end points included time-course changes in LS, total hip (TH), and femoral neck (FN) BMDs and bone turnover markers, and cumulative number of fractures.

What Was Measured

PubMed files the paper under topics including Bone Density, Bone Density Conservation Agents, Collagen Type I, Japan, Lumbar Vertebrae, Osteoporosis and Osteoporosis, Postmenopausal.

The authors tagged it with the keywords abaloparatide, bone formation, bone mineral density, fracture risk and vertebral fracture.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Abaloparatide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2022 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Abaloparatide compound page, all human trials.